Wondering what is tesa for weight loss? Tesamorelin is an injectable GHRH peptide studied for belly fat, not a standard obesity drug. Learn the facts.
Tesamorelin — nicknamed "tesa" in fitness and peptide forums — is an injectable growth hormone–releasing hormone (GHRH) analog that the FDA approved in 2010 to reduce excess abdominal fat in adults living with HIV and lipodystrophy. It is not approved for general weight loss, and it works very differently from GLP-1 medications such as semaglutide and tirzepatide. So the direct answer to what is tesa for weight loss is this: tesa is a narrow-use prescription peptide for visceral fat in a specific patient group, not a mainstream obesity drug.
Where the Name "Tesa" Comes From
"Tesa" is shorthand for tesamorelin, sold under the brand names Egrifta and Egrifta SV. The nickname spread through online peptide communities, where users shorten long drug names for convenience.
That casual label creates confusion. People searching for tesa often expect a weight loss injection similar to Ozempic or Mounjaro, then are surprised to learn it targets visceral fat in a specific medical context rather than overall body weight.
What Tesamorelin Is FDA-Approved For
The FDA approved tesamorelin for one indication: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is a daily subcutaneous injection, usually self-administered after training from a healthcare provider.
- Approved use: excess belly fat linked to HIV-related lipodystrophy
- Not approved for: general obesity, cosmetic weight loss, or body recomposition
- Form: prescription-only powder that must be mixed and injected
- Monitoring: periodic IGF-1 blood tests, because the drug raises IGF-1 levels
Tesamorelin is not FDA-approved for general weight loss. Anyone marketing "tesa" as a simple fat-loss shot is overselling a drug that was studied in a much narrower population.
How Tesa Works in the Body
Tesamorelin stimulates the pituitary gland to release more growth hormone, which in turn raises insulin-like growth factor 1 (IGF-1). Higher growth hormone signaling promotes lipolysis, the breakdown of stored fat, and that effect appears strongest in visceral fat around the organs.
Visceral fat is the deep belly fat linked to cardiovascular and metabolic risk. It is different from the pinchable subcutaneous fat most people picture when they think about losing weight.
Tesamorelin does not suppress appetite or slow stomach emptying the way GLP-1 drugs do. That single difference helps explain why it produces smaller changes in total body weight.
How Tesa Compares With Other Weight Loss Injections
If you are searching for what is the best injection for weight loss, the strongest clinical evidence belongs to GLP-1–based medications rather than tesamorelin.
| Option | Drug class | Typical clinical use | Average weight loss in trials | FDA status |
|---|---|---|---|---|
| Tesamorelin (Egrifta SV) | GHRH analog peptide | Visceral fat in HIV-associated lipodystrophy | Modest total weight change; targeted visceral fat reduction | Approved for that narrow use only |
| Semaglutide (Wegovy, Ozempic) | GLP-1 receptor agonist | Type 2 diabetes; chronic weight management | About 15% of body weight | Approved for weight management |
| Tirzepatide (Zepbound, Mounjaro) | Dual GIP and GLP-1 agonist | Type 2 diabetes; chronic weight management | About 20% or more of body weight | Approved for weight management |
| IGF-1 LR3 and similar research peptides | Research compound | Not a clinical therapy | No human obesity trial data | Not approved |
Many shoppers also wonder is semaglutide good for weight loss, and the trial data generally support it for adults with obesity or type 2 diabetes. When people compare tirzepatide vs semaglutide which is better for weight loss, tirzepatide has delivered larger average reductions in head-to-head studies, though side effects and cost often decide the choice.
The question is tirz safe for weight loss comes up constantly, and the honest answer is that tirzepatide carries boxed warnings for thyroid C-cell tumors, pancreatitis, and gallbladder disease, so it requires medical supervision.
Tesamorelin is also confused with other compounds sold online. What is igf-1 lr3 used for is a separate research question about muscle and recovery studies, and it has nothing to do with approved obesity treatment.
Safety, Side Effects, and Legal Status
Tesamorelin is a prescription drug in the United States. Buying "tesa" from a research chemical website is not the same as getting a prescription, and the purity and dosing of those products are not verified.
Reported side effects include injection site reactions, joint pain, muscle aches, swelling, and headache. Because tesamorelin raises IGF-1, it is not appropriate for people with active cancer, pituitary tumors, or certain hormone-sensitive conditions.
Anyone considering tesamorelin should talk with a physician who can review their cancer history, pituitary health, and current medications before any injection is used.
What the Research Shows and What to Ask Your Doctor
In trials of adults with HIV-associated lipodystrophy, tesamorelin reduced visceral adipose tissue by roughly 15% to 20% over 6 to 12 months, with much smaller changes in total body weight. That is a real metabolic benefit for that population, but it does not translate into dramatic weight loss for the general public.
If you are considering tesa, bring specific questions to a clinician:
- Does my medical history make tesamorelin safe for me?
- Would a GLP-1 medication be a better fit for my goals?
- How often would my IGF-1 levels need to be checked?
- What results are realistic in my case?
The bottom line is simple: tesamorelin is a legitimate prescription medication for a narrow condition, not a proven weight loss drug for everyone. Adults with obesity who want meaningful weight reduction should start with evidence-based options and medical guidance.
RELATED PEPTIDE TOPICTesa peptideFrequently Asked Questions
Is tesa FDA-approved for weight loss?
No. Tesamorelin is FDA-approved only for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It has never been approved for general obesity or cosmetic weight loss, so any product marketed that way is making an unsupported claim.
How much weight can you lose with tesamorelin?
In clinical trials, tesamorelin reduced visceral fat by roughly 15% to 20% over 6 to 12 months, while total body weight changed only slightly. Very little published data exists for people without HIV-associated lipodystrophy, so there is no reliable weight loss estimate for that group.
Is tesa the same as semaglutide or tirzepatide?
No. Tesamorelin is a growth hormone–releasing hormone analog that acts on the pituitary gland, while semaglutide and tirzepatide are GLP-1–based drugs that reduce appetite and slow digestion. The two classes produce very different results, and GLP-1 medications have far more evidence for treating obesity.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.